Proactive Investors
24 Aug 2026, 12:49 UTC · 2h ago
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
24 Aug 2026, 12:49 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Tiziana Life Sciences is initiating a Phase 2a clinical trial (BANYAN) evaluating intranasal foralumab for the treatment of ALS. — Entering a Phase 2a trial for a high-unmet-need disease like ALS creates a potential long-term value catalyst for the stock.
+0.40Tiziana has completed patient enrollment in a separate Phase 2 trial for intranasal foralumab in non-active Secondary Progressive Multiple Sclerosis. — Completion of enrollment is a key milestone that brings the company closer to reporting clinical data for MS.
+0.30The BANYAN trial is currently in its operational startup phase, with enrollment timing and participating sites yet to be announced. — The early stage of the trial means clinical data is far off, limiting immediate price movement.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is advancing its ALS pipeline with a Phase 2a clinical trial presentation and has completed enrollment in another Phase 2 trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
8h ago
